Kaleido Biosciences

Kaleido Biosciences
Name	Kaleido Biosciences
Industry	Biotechnology
Founded	2015
Founder	Alison Silva, David Stein, Michael Fischbach
Hq location	Lexington, Massachusetts
Key people	Daniel Menichella (CEO)
Products	Microbiome Metabolic Therapies (MMTs)

Kaleido Biosciences was a clinical-stage healthcare company focused on leveraging the human microbiome to develop novel therapeutic candidates. The company pioneered a platform to discover and develop Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and composition of the microbiome. Its research aimed to address a range of conditions, including complications in patients with mild-to-moderate COVID-19 and various metabolic and inflammatory diseases. Founded in 2015 and based in Lexington, Massachusetts, the company ceased operations and was delisted from the NASDAQ in 2022 following unsuccessful clinical trials and financial challenges.

Company Overview

Kaleido Biosciences was incorporated in 2015 by founders Alison Silva, David Stein, and Michael Fischbach, a professor at Stanford University known for his work in microbial chemistry. The company established its headquarters in the biotechnology hub of Lexington, Massachusetts, within the greater Boston area. Its operational model centered on a rapid, cost-effective discovery platform to develop synthetic glycans, positioning it within the competitive field of microbiome therapeutics alongside firms like Seres Therapeutics and Vedanta Biosciences. Kaleido conducted its initial public offering in 2019, raising capital to advance its pipeline, but ultimately faced significant hurdles in late-stage clinical development.

Technology and Platform

The company's core technology involved Microbiome Metabolic Therapies (MMTs), which are orally administered synthetic glycans designed to act as substrates for specific bacteria in the gut microbiome. This approach aimed to selectively modulate microbial metabolism and community structure, producing beneficial metabolites like short-chain fatty acids. The platform utilized high-throughput screening in partnership with institutions like the Broad Institute to rapidly test compounds against human microbiomes ex vivo. This strategy was distinct from live biotherapeutic products or fecal microbiota transplants, focusing instead on influencing the ecosystem's function. The science was built upon foundational research from Michael Fischbach's lab and collaborations with experts at University of California, San Francisco.

Clinical Development and Programs

Kaleido advanced several candidates into clinical trials, primarily targeting gastrointestinal and metabolic conditions. Its lead program, KB109, was evaluated for the treatment of mild-to-moderate COVID-19 in outpatient settings to prevent disease progression. Another significant candidate, KB195, targeted urea cycle disorders and entered a collaboration with the U.S. Food and Drug Administration's Rare Disease Program. The company also ran trials for KB174 for hepatic encephalopathy and explored applications in atopic dermatitis. However, a pivotal Phase 2/3 trial for KB109 failed to meet its primary endpoint in 2021, leading to a strategic reassessment and eventual termination of most programs.

Collaborations and Partnerships

To bolster its research and development, Kaleido engaged in several key strategic alliances. A major multi-year collaboration was formed with the Broad Institute of MIT and Harvard to employ machine learning and genomic tools for biomarker discovery. The company also partnered with the U.S. Department of Defense under an agreement with the Defense Threat Reduction Agency to develop MMTs for gastrointestinal health. Furthermore, Kaleido worked with the Cystic Fibrosis Foundation to explore therapies for gut dysfunction in cystic fibrosis patients. These partnerships provided non-dilutive funding and access to expertise but were insufficient to sustain the company after clinical setbacks.

Financial History and Stock Performance

Kaleido Biosciences completed its initial public offering in February 2019, listing on the NASDAQ under the ticker symbol "KLDO" and raising approximately $64 million. Subsequent financings included a private placement in 2020 and an at-the-market equity program. Following the negative topline results from its KB109 trial in late 2021, the company's stock price declined precipitously, losing over 90% of its value. In early 2022, facing depleted cash reserves and an inability to secure additional funding, Kaleido announced a reduction in force, ceased all operations, and initiated a voluntary delisting from the NASDAQ. The remaining assets were later acquired by ContraFect Corporation in 2023.

Leadership and Governance

The company was led by Chief Executive Officer Daniel Menichella, who joined in 2020 after serving as CEO of CureVac AG. Other key executives included Chief Medical Officer Johannes Blom and Chief Financial Officer Michael Bonney, the former CEO of Cubist Pharmaceuticals. The Board of Directors featured industry veterans such as Cameron Durrant and Mya Thomae, who provided guidance in drug development and regulatory strategy. The scientific advisory board included prominent researchers like Michael Fischbach and Justin Sonnenburg from Stanford University, helping to steer the company's research direction in microbiome science.

Category:Biotechnology companies of the United States Category:Companies based in Lexington, Massachusetts Category:Defunct pharmaceutical companies of the United States